awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q35200337-0C612204-BB9D-41DF-A067-E871162047F3
Q35200337-0C612204-BB9D-41DF-A067-E871162047F3
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35200337-0C612204-BB9D-41DF-A067-E871162047F3
Role of HGF/MET axis in resistance of lung cancer to contemporary management.
P2860
Q35200337-0C612204-BB9D-41DF-A067-E871162047F3
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35200337-0C612204-BB9D-41DF-A067-E871162047F3
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
be35d77318b71d0907edfea934a0e87b26f69182
P2860
Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.